RKT

Reckitt Benckiser Group plc occupies an unusual position in the European consumer staples landscape. It is simultaneously one of the most recognizable brand portfolios in the world and one of the most strategically uncertain major consumer goods companies in the STOXX 600. The company owns Lysol, Dettol, Durex, Nurofen, Finish, Air Wick, and Enfamil, names that collectively reach billions of consumers. Yet Reckitt's market capitalization of roughly GBP 33 billion places it at a significant discount to where it traded just a few years ago, and the share price near 5,080p, well beneath the 52-week high of 6,523p, tells a story the brand names alone cannot.

The central analytical question is not whether Reckitt's brands are strong. They are. The question is whether a company that spent more than a decade assembling a sprawling health, hygiene, and nutrition conglomerate through acquisitions can successfully disassemble and refocus itself without destroying the very portfolio coherence that justified its premium multiple. Reckitt is not a company that defines its markets. It is a company that competes in markets defined by others: by Procter and Gamble in home care, by Johnson and Johnson in consumer health, by Haleon in OTC pharmaceuticals, by Nestle in infant nutrition. This distinction matters enormously for understanding Reckitt's structural position.

The L17X insight here is precise: Reckitt's problem is not that its brands lack consumer loyalty but that no single brand or category gives it the structural power to set the terms of competition. It participates in nearly every aisle of the pharmacy and supermarket without dominating any of them. The company's strategic pivot under Kris Licht, who became CEO in late 2024, toward a leaner, more focused portfolio is an acknowledgment that breadth without depth is not a moat. It is a cost structure.